-
Mashup Score: 14
Key Points. Patients treated with next generation BTKi therapy, acalabrutinib, see a >8 fold increase in ventricular arrhythmia and sudden death events.Ventr
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
RT @md_addison: Ventricular Arrhythmias and Sudden Cardiac Death events after Acalabrutinib initiation: https://t.co/2AuruJ8O4i A >8-fold…
-
-
Mashup Score: 12Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study - 2 year(s) ago
Abstract Background More than 80% of adult patients diagnosed with cancer survive long term. Long-term complications of cancer and its therapies may increase the risk of cardiovascular disease (CVD…
Categories: Cardiologists, Latest HeadlinesTweet-
RT @avirupguha: ARIC-Cancer study: https://t.co/Dttw8yoRBQ Cardiovascular Disease Risk Among Cancer Survivors: The ARIC Study Cancer surv…
-
ARIC-Cancer study: https://t.co/Dttw8yoRBQ Cardiovascular Disease Risk Among Cancer Survivors: The ARIC Study Cancer survivors had a higher risk of CVD in the contemporary cohort compared to older cohorts. Interestingly not with PC! @nih_nhlbi https://t.co/zQMJPMkIc1
-
-
Mashup Score: 7Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure: - 2 year(s) ago
Abstract Background Beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors (SGLT2i), known as quadrup…
Categories: Cardiologists, Latest HeadlinesTweet-
RT @avirupguha: Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure @jaccjournals https://t.co/wPHso5g7gX…
-
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure @jaccjournals https://t.co/wPHso5g7gX @YaleCardiology @yaleHFdoc @nihardesai927 - triple therapy - $159 and 4 pillars - $2217 if you have medicare. Is financial toxicity worth the gain in NNT?
-
-
Mashup Score: 18CCON - 2 year(s) ago
Global Cardio-Oncology Summit 2022Event DetailsDate: October 6-7, 2022Location: Fairmont Royal York Hotel100 Front Street WToronto, OntarioM5J 1E3, Canada Provided by: Canadian Cardiac Oncology Network | International CardiOncology Society In collaboration with: Ted Rogers Centre for Heart Research About this Year’s Conference The GCOS summit models a leading-edge…
Source: cardiaconcology.caCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ICOSociety: Mark off the #cardioonc event of the year in @torontolife Register: https://t.co/TyqcU9jQTs Dates: 6-7 Oct @dineshpmcc1…
-
RT @ICOSociety: Mark off the #cardioonc event of the year in @torontolife Register: https://t.co/TyqcU9jQTs Dates: 6-7 Oct @dineshpmcc1…
-
RT @ICOSociety: Mark off the #cardioonc event of the year in @torontolife Register: https://t.co/TyqcU9jQTs Dates: 6-7 Oct @dineshpmcc1…
-
-
Mashup Score: 10Longitudinal Changes in Circulating Metabolites and Lipoproteins After Breast Cancer Treatment - 2 year(s) ago
The multimodal treatment of breast cancer may induce long term effects on the metabolic profile and increase the risk of future cardiovascular disease. In this study, we characterized longitudinal changes in serum lipoprotein subfractions and metabolites after breast cancer treatment, aiming to determine the long-term effect of different treatment modalities. Further, we investigated the…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @avirupguha: Longitudinal Changes in Circulating Metabolites and Lipoproteins After #breastcancer Treatment https://t.co/sO5O8Cui6K #ca…
-
Longitudinal Changes in Circulating Metabolites and Lipoproteins After #breastcancer Treatment https://t.co/sO5O8Cui6K #cardioonc @FrontiersIn
-
-
Mashup Score: 13Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines: - 3 year(s) ago
Abstract Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among patients with established heart failure. Despite supportive basic science studies, there are no data on…
Source: JACC: Heart FailureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @avirupguha: From @jaccjournals https://t.co/AOKHRmiSHV SGLT2 inhibitors in anthracycline treated patients. Great work by @TomasNeilan @…
-
From @jaccjournals https://t.co/AOKHRmiSHV SGLT2 inhibitors in anthracycline treated patients. Great work by @TomasNeilan @dineshpmcc1 and colleagues #cardioonc. Would be a great clinical trial as suggested.
-
-
Mashup Score: 6
Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of a clonally expanded hematopoietic stem cell caused by a leukemogenic mutatio…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Clonal hematopoiesis of indeterminate potential (CHIP): Linking somati... https://t.co/inaJXNM7Qm #CardioOnc @ICOSociety @EuroCardioOnc
-
RT @OSUCardioOnc: Clonal hematopoiesis of indeterminate potential (CHIP): Linking somati... https://t.co/inaJXNM7Qm #CardioOnc @ICOSociety…
-
-
Mashup Score: 9Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience - 3 year(s) ago
Objective Antimicrotubular agents are among the most commonly used classes of chemotherapeutic agents, but the risk of cardiovascular adverse events (CVAEs) remains unclear. Our objective was to study the CVAEs associated with antimicrotubular agents. Methods The Food and Drug Administration’s Adverse Event Reporting System was used to study CVAEs in adults from 1990 to 2020. Reported…
Source: Open HeartCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @avirupguha: Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience https://t.co/uGUks6aJ2y Ex…
-
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience https://t.co/uGUks6aJ2y Excellent work by @AksheeBatra Take home: Anti-microtubular agents are more toxic in combination with already known toxic agents #cardioonc
-
RT @md_addison: Ventricular Arrhythmias and Sudden Cardiac Death events after Acalabrutinib initiation: https://t.co/2AuruJ8O4i A >8-fold…